Moreover, our proof-of-principle study focused on the driver mutations BRAF and NRAS, which account for up to 70% of melanomas, and are well suited to this purpose because of the low likelihood of clonal diversity with trunk mutations such as these in melanoma. This evidence concerns the gene BRAF and melanoma.